» Articles » PMID: 37634642

Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging

Overview
Journal Korean J Radiol
Specialty Radiology
Date 2023 Aug 27
PMID 37634642
Authors
Affiliations
Soon will be listed here.
Abstract

C-X-C motif chemokine receptor 4 (CXCR4) plays a key role in various physiological functions, such as immune processes and disease development, and can influence angiogenesis, proliferation, and distant metastasis in tumors. Recently, several radioligands, including peptides, small molecules, and nanoclusters, have been developed to target CXCR4 for diagnostic purposes, thereby providing new diagnostic strategies based on CXCR4. Herein, we focus on the recent research progress of CXCR4-targeting radioligands for tumor diagnosis. We discuss their application in the diagnosis of hematological tumors, such as lymphomas, multiple myelomas, chronic lymphocytic leukemias, and myeloproliferative tumors, as well as nonhematological tumors, including tumors of the esophagus, breast, and central nervous system. Additionally, we explored the theranostic applications of CXCR4-targeting radioligands in tumors. Targeting CXCR4 using nuclear medicine shows promise as a method for tumor diagnosis, and further research is warranted to enhance its clinical applicability.

Citing Articles

A Look to the Future: Potential Theranostic Applications in Head and Neck Tumors.

Oldan J, Solnes L, Chin B, Rowe S Cancers (Basel). 2025; 17(4).

PMID: 40002288 PMC: 11854056. DOI: 10.3390/cancers17040695.


PET imaging of CXCR4 expression using [F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors.

Cheng K, Wang S, Liu T, Pei J, Wang S, Liu J Theranostics. 2024; 14(16):6337-6349.

PMID: 39431004 PMC: 11488100. DOI: 10.7150/thno.99025.


New Oncologic Imaging Section in the .

Park S Korean J Radiol. 2024; 25(1):6-7.

PMID: 38184763 PMC: 10788602. DOI: 10.3348/kjr.2023.1165.

References
1.
Fu P, Tian L, Cao X, Li L, Xu P, Zhao C . Imaging CXCR4 Expression with (99m)Tc-Radiolabeled Small-Interference RNA in Experimental Human Breast Cancer Xenografts. Mol Imaging Biol. 2015; 18(3):353-9. DOI: 10.1007/s11307-015-0899-4. View

2.
Herhaus P, Lipkova J, Lammer F, Yakushev I, Vag T, Slotta-Huspenina J . CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. J Nucl Med. 2020; 61(12):1765-1771. DOI: 10.2967/jnumed.120.241703. View

3.
Arya M, Patel H, McGurk C, Tatoud R, Klocker H, Masters J . The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol. 2005; 4(4):291-303. View

4.
Weiss I, Jacobson O . Molecular imaging of chemokine receptor CXCR4. Theranostics. 2013; 3(1):76-84. PMC: 3563082. DOI: 10.7150/thno.4835. View

5.
Hiller D, Meschonat C, Kim R, Li B, Chu Q . Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. Surgery. 2011; 150(3):459-65. DOI: 10.1016/j.surg.2011.07.005. View